Values are as of January each year. A total of 1,246 companies were included in the calculation for 2025, 1,326 for 2024, 1,236 for 2023, 1,427 for 2022, 1,399 for 2021, 1,305 for 2020 and 1,230 for 2019.Â
Enterprise value = Market value of equity + Market value of debt - Cash. EBITDA = Estimated by adding depreciation and amortization back to operating income (EBIT). Only positive EBITDA companies.
Citation formats
EV/EBITDA in the health and pharmaceuticals sector in the U.S. 2019-2026, by industry
In the United States, the median value of enterprise value to earnings before interest, tax, depreciation and amortization (EV/EBITDA) in the health and pharmaceuticals sector as of 2026 was a multiple of approximately ***. Companies operating in the * industries saw the highest valuation multiple with EV/EBITDA ratio of approximately ***** in 2026, down from in 2025.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Leonard N. Stern School of Business. (January 5, 2026). Average EV/EBITDA multiples in the health and pharmaceuticals sector in the United States from 2019 to 2026, by industry [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved August 04, 2026, from /statistics/1030072/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-united-states/
Leonard N. Stern School of Business. "Average EV/EBITDA multiples in the health and pharmaceuticals sector in the United States from 2019 to 2026, by industry." Chart. January 5, 2026. ÌÇÐÄÆƽâ°æ. Accessed August 04, 2026. /statistics/1030072/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-united-states/
Leonard N. Stern School of Business. (2026). Average EV/EBITDA multiples in the health and pharmaceuticals sector in the United States from 2019 to 2026, by industry. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: August 04, 2026. /statistics/1030072/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-united-states/
Leonard N. Stern School of Business. "Average Ev/Ebitda Multiples in The Health and Pharmaceuticals Sector in The United States from 2019 to 2026, by Industry." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 5 Jan 2026, /statistics/1030072/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-united-states/
Leonard N. Stern School of Business, Average EV/EBITDA multiples in the health and pharmaceuticals sector in the United States from 2019 to 2026, by industry ÌÇÐÄÆƽâ°æ, /statistics/1030072/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-united-states/ (last visited August 04, 2026)
Average EV/EBITDA multiples in the health and pharmaceuticals sector in the United States from 2019 to 2026, by industry [Graph], Leonard N. Stern School of Business, January 5, 2026. [Online]. Available: /statistics/1030072/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-united-states/
